The depletion of B-cells using anti-CD20 monoclonal antibodies resulted in significantly diminished pro-inflammatory responses of CD4+ and CD8+ T-cells as well as myeloid cells, and provided evidence of the use of these agents as highly effective therapies both in relapsing and progressive MS. Here, CD4 is linked to myeloid sarcoma.